Why Predicitive Oncology Stock Is Soaring
Why Predicitive Oncology Stock Is Soaring
"We have already demonstrated the capabilities of our active machine learning platform to selectively utilize our diverse patient samples preserved in our biobank to predict responses to drugs with a very high degree of accuracy," said Predictive Oncology Inc. (NASDAQ:POAI) shares are blasting higher Thursday after the company announced it is expanding its AI and machine learning driven drug discovery platform to pursue discovery of novel biomarkers.
Predictive Oncology Inc.（纳斯达克股票代码：POAI）周四股价上涨，此前该公司宣布将扩大其人工智能和机器学习驱动的药物发现平台，以探索新型生物标志物。
The Details:
细节：
Predictive Oncology said its latest biomarker discovery initiative stems, in part, from results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital. In that study, Predictive Oncology successfully developed muti-omic machine learning models that identified key features that could more accurately predict both short-term and long-term survival outcomes among ovarian cancer patients as compared to clinical data alone.
Predictive Oncology表示，其最新的生物标志物发现计划在一定程度上源于UPMC Magee-Womens Hospital的回顾性卵巢癌研究的结果。在该研究中，Predictive Oncology成功开发了多组学机器学习模型，该模型确定了关键特征，与单独的临床数据相比，这些特征可以更准确地预测卵巢癌患者的短期和长期存活结果。
"We have already demonstrated the capabilities of our active machine learning platform to selectively utilize our diverse patient samples preserved in our biobank to predict responses to drugs with a very high degree of accuracy," said Arlette H. Uihlein, MD, SVP, medical director at Predictive Oncology.
Predictive Oncology医学总监、高级副总裁、医学总监Arlette H. Uihlein表示：“我们已经证明了主动机器学习平台能够选择性地利用保存在生物库中的各种患者样本，以非常高的精度预测对药物的反应。”
"We are now taking this one step further by applying state-of-the-art deep learning approaches for biomarker discovery related to both patient overall survival (OS) and drug response, which can be done with existing resources. Our platform enables us to apply deep learning to the correct patient cohorts and accelerate the initial stages of biomarker discovery."
“我们现在更进一步，应用最先进的深度学习方法来发现与患者总存活率（OS）和药物反应相关的生物标志物，这可以利用现有资源来完成。我们的平台使我们能够将深度学习应用于正确的患者群组，并加快生物标志物发现的初始阶段。”
According to data from Benzinga Pro, Predictive Oncology shares are trading on heavy volume Thursday and reached an intraday high of $2.96 per share.
根据Benzinga Pro的数据，Predictive Oncology的股票周四交易量很大，盘中达到每股2.96美元的高点。
Should I Sell My POAI Stock?
我应该卖出我的 POAI 股票吗？
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
在决定持有或出售股票时，投资者应考虑其时间范围、未实现收益和总回报。
Shares of Predictive Oncology have decreased by 50.57% in the past year. The stock has risen 63% over the past month.
在过去的一年中，预测肿瘤学的份额下降了50.57％。该股在过去一个月中上涨了63％。
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Predictive Oncology stock currently has an RSI of 46.66, indicating neutral conditions.
投资者也可以考虑市场动态。相对强弱指数可用于表明股票是超买还是超卖。预测肿瘤学股票目前的相对强弱指数为46.66，表明状况中性。
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
要访问高级制图和分析工具以及股票数据，请查看 Benzinga PRO。免费试用。
POAI Price Action: According to Benzinga Pro, Predictive Oncology shares are up 64.4% at $1.75 at the time of publication Thursday.
POAI价格走势：根据Benzinga Pro的数据，预测肿瘤学股价在周四发布时上涨了64.4％，至1.75美元。
Read Also:
另请阅读：
- Viking Therapeutics Stock Climbs On Q2 EPS Beat
- Viking Therapeutics股票在第二季度每股收益上涨后上涨
Image: Shutterstock
图片：Shutterstock